Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-03-10 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
董事会对独立董事独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a statement from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange listing rules. It is a specialized opinion on the independence self-assessment of independent directors, not a full report or financial statement. The document is short (438 characters) and focuses on governance compliance and board member independence. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-03-10 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2025-03-10 Chinese
董事、监事和高级管理 人员所持公司股份及其 变动管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system regarding the holdings and changes of shares by the company's directors, supervisors, and senior management. It includes rules on reporting, disclosure, restrictions on trading, and penalties related to insider trading and shareholding changes. The content focuses on governance and compliance with securities laws and stock exchange regulations. There is no indication that this is an announcement, a financial report, or a regulatory filing of results or transactions. Instead, it is a governance document outlining internal rules and procedures for managing shareholdings of key personnel. Therefore, the document best fits the category of Governance Information (CGR). The document length and detail support this classification with high confidence.
2025-03-10 Chinese
关于2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the fiscal year 2025. It includes extensive tables of transaction amounts, descriptions of related parties, pricing principles, and explanations of the transactions' purposes and impacts. The content focuses on operational and financial dealings with related parties rather than financial results or audit opinions. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a brief announcement or a certification but a substantive disclosure about related party transactions, which is typically classified under Regulatory Filings (RNS) when it does not fit other specific categories. Given the detailed nature and the focus on compliance and disclosure, the best fit is Regulatory Filings (RNS).
2025-03-10 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including total assets, net profit, earnings per share, and shareholder information. The document also references the full annual report and advises investors to read the full report for comprehensive information. The content includes comprehensive financial performance data and business overview for the fiscal year 2024, which aligns with the characteristics of an Annual Report (10-K). The document length is under 5,000 characters but it is not merely an announcement or a notice of report publication; it contains substantive financial data and analysis. Therefore, it should be classified as an Annual Report (10-K). FY 2024
2025-03-10 Chinese
董事会审计委员会对会计师事务所2024年度履行监督职责情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report by the Board Audit Committee on the performance of the accounting firm (auditor) for the fiscal year 2024. It discusses the auditor's qualifications, audit plan, execution of audit work, and the audit committee's approval of the 2024 financial report and internal control evaluation report. The document is focused on the audit process and the auditor's supervision duties rather than the full annual report itself. It is a standalone audit-related report, not the full Annual Report (10-K). The document length is short (1066 characters), but it contains substantive content about the audit process and results, not just an announcement or certification. Therefore, it fits best under Audit Report / Information (AR). FY 2024
2025-03-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.